Rennova Health, Inc. (NASDAQ:RNVA)- Active Mix Cap Retreated Movers: Glu Mobile Inc. (NASDAQ:GLUU)

Rennova Health, Inc. (NASDAQ:RNVA) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -8.42% to $0.15. Rennova Health, Inc. (RNVA) reported financial results for the three and nine months ended September 30, 2016, and provided a business update.

Rennova’s chief executive officer, Seamus Lagan stated that their third quarter financial results are disappointing and do not reflect the continued performance and success the Company has had in recent months in securing new customers in all divisions of their business.

He added, “Sales for the third quarter were less than the second quarter as a result of the adjustment of our model towards business for which we are more likely to secure payment, and longer onboarding and integration times to start new customers. Underlying sales in our software division have grown in the third quarter, and we achieved a number of milestones and advanced several initiatives to create cost efficiencies and drive growth in the fourth quarter and throughout 2017.

The share price of RNVA attracts active investors, as stock price of week volatility recorded 65.64%. The stock is going forward to its 52-week low with 87.03% and lagging behind from its 52-week high price with -94.34%.

Glu Mobile Inc. (NASDAQ:GLUU) [Trend Analysis] moved down reacts as active mover, shares a decrease -1.85% to traded at $2.12 and the percentage gap between open changing to regular change was 0.01%. Fundamentalist can give brighter side of a picture but an analyst can glow the darker parts stored in any investment. Let us view how analysts have ranked GLUU in recent few months. In ratings table the GLUU given BUY ratings by 3 analysts in current phase. While 4 number of analysts gave ratings for HOLD in current. As per remarks given by WSJ, overall consensus pool recommend it as Overweight security.

The stock was assessed in terms of profitability as current quarter EPS estimate trends showed $-0.07 at current month while compared with $-0.07 in a month ago. The stock next year first quarter current estimate trend for EPS was for $-0.06 and on annual basis FY 2016 estimate trends at current was for $-0.39 as compared to one month ago of $-0.39, and for next year per share earnings estimates have $-0.11.

The firm’s current ratio calculated as 3.10 for the most recent quarter. The firm past twelve months price to sales ratio was 1.32 and price to cash ratio remained 1.92. As far as the returns are concern, the return on equity was recorded as -25.60% and return on investment was -2.10% while its return on asset stayed at -19.40%. The firm has total debt to equity ratio measured as 0.01.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *